Litcius/Paper detail

Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial

Ho‐Young Yhim, T. Kim, Seung Ju Kim, Ho‐Jin Shin, Youngil Koh, Jin Sung Kim, Jinny Park, G.S. Park, Woo Seob Kim, Joon Ho Moon, Deok‐Hwan Yang

2020Annals of Oncology27 citationsDOIOpen Access PDF

Topics & Concepts

MedicineGemcitabineNeutropeniaInternal medicinePhases of clinical researchGastroenterologyRefractory (planetary science)Adverse effectPeripheral T-cell lymphomaFebrile neutropeniaLymphomaOncologySurgeryChemotherapyImmunologyT cellImmune systemAstrobiologyPhysicsLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCutaneous lymphoproliferative disorders research
Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial | Litcius